Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Efinopegdutide: Evidence Summary
Evidence summary for Efinopegdutide across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Efinopegdutide overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| NAFLD/liver fat reduction | Tier B | 1 | Phase 2a RCT showed 72.7% liver fat reduction, superior to semaglutide |
| Obesity/weight loss | Tier C | 0 | Weight loss observed as secondary endpoint — no dedicated obesity trial |
| MASH with fibrosis | Tier D | 0 | No MASH-specific fibrosis endpoint trials completed |
References (1)
- Efinopegdutide vs semaglutide in NAFLD: Phase 2a randomized trial — Harrison SA, et al. . Nature Medicine (2023) PMID: 37355043